124 related articles for article (PubMed ID: 22336524)
21. The long-term effect of recombinant methionyl human leptin therapy on hyperandrogenism and menstrual function in female and pituitary function in male and female hypoleptinemic lipodystrophic patients.
Musso C; Cochran E; Javor E; Young J; Depaoli AM; Gorden P
Metabolism; 2005 Feb; 54(2):255-63. PubMed ID: 15690321
[TBL] [Abstract][Full Text] [Related]
22. Hyperinsulinemia in hyperthecosis of the ovaries.
Nagamani M; Van Dinh T; Kelver ME
Am J Obstet Gynecol; 1986 Feb; 154(2):384-9. PubMed ID: 3511712
[TBL] [Abstract][Full Text] [Related]
23. Increased bioactive luteinizing hormone levels and bio/immuno ratio in women with hyperthecosis of the ovaries: possible role of hyperinsulinemia.
Nagamani M; Osuampke C; Kelver ME
J Clin Endocrinol Metab; 1999 May; 84(5):1685-9. PubMed ID: 10323400
[TBL] [Abstract][Full Text] [Related]
24. Hirsutism and virilism in women.
Kirschner MA
Spec Top Endocrinol Metab; 1984; 6():55-93. PubMed ID: 6084314
[TBL] [Abstract][Full Text] [Related]
25. Oral contraceptive therapy for polycystic ovary disease after chronic gonadotropin-releasing agonist administration. Predictors of continued ovarian suppression.
Elkind-Hirsch KE; Anania C; Malinak R
J Reprod Med; 1996 Sep; 41(9):645-52. PubMed ID: 8887188
[TBL] [Abstract][Full Text] [Related]
26. Overnight secretion pattern of growth hormone, sex hormone binding globulin, insulin-like growth factor-1 and its binding protein in obese and non-obese women with polycystic ovarian disease.
Insler V; Barash A; Shoham Z; Koistinen R; Seppala M; Hen M; Lunenfeld B; Zadik Z
Isr J Med Sci; 1994 Jan; 30(1):42-7. PubMed ID: 7511134
[TBL] [Abstract][Full Text] [Related]
27. [Molecular background of hyperandrogenism of ovarian origin].
Katulski K; Warenik-Szymankiewicz A; Trzeciak WH
Ginekol Pol; 1999 May; 70(5):315-22. PubMed ID: 10462973
[TBL] [Abstract][Full Text] [Related]
28. Clinical Case Seminar: Postmenopausal androgen excess-challenges in diagnostic work-up and management of ovarian thecosis.
Mamoojee Y; Ganguri M; Taylor N; Quinton R
Clin Endocrinol (Oxf); 2018 Jan; 88(1):13-20. PubMed ID: 28980338
[TBL] [Abstract][Full Text] [Related]
29. Primary polycystic ovary syndrome in a premenarchal girl. A case report.
Rao JK; Chihal HJ; Johnson CM
J Reprod Med; 1985 Apr; 30(4):361-5. PubMed ID: 3925138
[TBL] [Abstract][Full Text] [Related]
30. Pioglitazone for treating polycystic ovary syndrome in non-obese women of reproductive age with different clinical presentations.
Koo YA; Shin SY; Yoon BK; Choi D
Gynecol Endocrinol; 2007; 23(8):461-7. PubMed ID: 17852414
[TBL] [Abstract][Full Text] [Related]
31. Luteinizing hormone, adrenal androgenesis, and polycystic ovarian disease.
Polansky S
Obstet Gynecol; 1975 Apr; 45(4):451-4. PubMed ID: 1121374
[TBL] [Abstract][Full Text] [Related]
32. Metabolic characteristics of women with polycystic ovaries and oligo-amenorrhoea but normal androgen levels: implications for the management of polycystic ovary syndrome.
Barber TM; Wass JA; McCarthy MI; Franks S
Clin Endocrinol (Oxf); 2007 Apr; 66(4):513-7. PubMed ID: 17371468
[TBL] [Abstract][Full Text] [Related]
33. Diagnostic Challenges in Ovarian Hyperthecosis: Clinical Presentation with Subdiagnostic Testosterone Levels.
Shah S; Torres C; Gharaibeh N
Case Rep Endocrinol; 2022; 2022():9998807. PubMed ID: 35087692
[TBL] [Abstract][Full Text] [Related]
34. Hyperthecosis syndrome. Clinical, endocrinologic and histologic findings.
Karam K; Hajj S
Acta Obstet Gynecol Scand; 1979; 58(1):73-9. PubMed ID: 419961
[TBL] [Abstract][Full Text] [Related]
35. Ovarian hyperthecosis in the context of an adrenal incidentaloma in a postmenopausal woman.
Marcondes JA; Curi DD; Matsuzaki CN; Barcellos CR; Rocha MP; Hayashida SA; Baracat EC
Arq Bras Endocrinol Metabol; 2008 Oct; 52(7):1184-8. PubMed ID: 19082308
[TBL] [Abstract][Full Text] [Related]
36. The investigation and management of severe hyperandrogenism pre- and postmenopause: non-tumor disease is strongly associated with metabolic syndrome and typically responds to insulin-sensitization with metformin.
Vaikkakara S; Al-Ozairi E; Lim E; Advani A; Ball SG; James RA; Quinton R
Gynecol Endocrinol; 2008 Feb; 24(2):87-92. PubMed ID: 18210332
[TBL] [Abstract][Full Text] [Related]
37. Ovarian Leydig cell tumor in a peri-menopausal woman with severe hyperandrogenism and virilization.
Nardo LG; Ray DW; Laing I; Williams C; McVey RJ; Seif MW
Gynecol Endocrinol; 2005 Oct; 21(4):238-41. PubMed ID: 16316848
[TBL] [Abstract][Full Text] [Related]
38. Ovarian hyperthecosis, diabetes and hirsuties in post-menopausal women.
Barth JH; Jenkins M; Belchetz PE
Clin Endocrinol (Oxf); 1997 Feb; 46(2):123-8. PubMed ID: 9135690
[TBL] [Abstract][Full Text] [Related]
39. Management of postmenopausal virilization.
Alpañés M; González-Casbas JM; Sánchez J; Pián H; Escobar-Morreale HF
J Clin Endocrinol Metab; 2012 Aug; 97(8):2584-8. PubMed ID: 22669303
[TBL] [Abstract][Full Text] [Related]
40. Specific binding sites for insulin-like growth factor I in the ovarian stroma of women with polycystic ovarian disease and stromal hyperthecosis.
Nagamani M; Stuart CA
Am J Obstet Gynecol; 1990 Dec; 163(6 Pt 1):1992-7. PubMed ID: 2175151
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
